Cancer Patients With Private Insurance Pay $0 for Genetic Counseling
In a cohort of privately-insured patients, the median out-of-pocket cost for genetic counseling was $0.
Gastrointestinal Cancers News
GASTROINTESTINAL CANCER ADVISOR
Gastrointestinal Cancers News
Neoadjuvant mFOLFIRINOX Is Reference Regimen for Borderline Resectable PDAC
Modified FOLFIRINOX represents a reference regimen for patients with borderline resectable pancreatic ductal adenocarcinoma, according to researchers.
Cancer Patients With HIV May Not Receive Equitable Treatment
Cancer patients with HIV do not receive curative or palliative care in the same way as their HIV-negative peers.
Hearing Loss, Tinnitus Common After Neurotoxic Chemo for Cancer
Rates of hearing loss and tinnitus were similar for cancer survivors who received a platinum agent alone, a taxane alone, or both a platinum agent and a taxane.
Radiotherapy for Prostate Cancer May Increase Risk of Second Primary Cancer
Patients treated with radiotherapy had a greater risk of second primary cancer when compared with patients who underwent surgery or surveillance.
Laparoscopic Surgery Noninferior for Gastric Cancer at Five Years
At 5 years, OS and RFS rates were similar with laparoscopic surgery and open distal gastrectomy.
Risk of Second Cancer Lower With FOLFOX Than With FULFOL
Overall, adjuvant chemotherapy does not appear to increase the risk of second cancers for patients with stage III-IV colon cancer.
ICIs Appear Safer Than TKIs for Advanced Hepatocellular Carcinoma
A meta-analysis suggests that immune checkpoint inhibitors are safer than tyrosine kinase inhibitors as neoadjuvant therapy for advanced hepatocellular carcinoma.
Early Changes in ctDNA May Predict Treatment Outcomes in Advanced Cancer
Detection of ctDNA and early changes in ctDNA levels may predict treatment outcomes in patients with advanced solid tumors.
A Banana a Day May Keep Upper GI Cancers Away
For patients with Lynch syndrome, taking a daily supplement containing resistant starch reduced the risk of upper gastrointestinal cancers.
Significant County-Level Variability Seen With Gastrointestinal Cancers
Counties in the Southeastern United States primarily accounted for the highest 5% of mortality rates for gastric, pancreatic, and colorectal cancer.
Illegitimate Online Pharmacies May Put Cancer Patients at Risk
Illegitimate online pharmacies are selling imatinib without a prescription, making false claims about being registered with regulatory bodies, and failing to provide patients with drug-related warnings.
Medically Integrated Dispensing on the Rise in US Oncology Practices
From 2010 to 2019, the percentage of oncology practices with medically integrated dispensing more than doubled.
Dietary Coaching Intervention Improves Posttreatment Care for Rectal Cancer Survivors
Researchers developed a strategy for providing rectal cancer survivors with dietary guidance and posttreatment care.
Surveillance of High-Risk Group May Downstage Pancreatic Cancer
The median survival was 9.8 years for patients with screen-detected PDAC and 1.5 years for those with PDAC detected outside of surveillance.
Model Including Marital Status Prognostic for Early Gastric Cancer
Age at diagnosis, sex, histology, T stage, surgery, tumor size, and marital status were independent predictors of overall survival, researchers found.
Blood Type Linked to Outcomes of Immune Checkpoint Inhibitor Therapy in Metastatic Cancer
Blood type may influence response to immune checkpoint inhibitor therapy among patients with metastatic cancer, a study suggests.
AGA Releases Position Statements on Colorectal Cancer Screening
The American Gastroenterological Association outlined guiding principles to improve colorectal cancer screening nationwide, highlighting a need to eliminate financial barriers for patients.
113-Gene Signature May Predict Long-Term HCC Risk in NAFLD
A 113-gene signature may predict the long-term risk of incident hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.
Cabozantinib Plus Atezolizumab Improves PFS, Not OS in Hepatocellular Carcinoma
Cabozantinib plus atezolizumab improved progression-free survival when compared with sorafenib.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Expertscape
Loading... 
Loading...